Improving HF Population Health Management and Collaborative Care
Ryan Haumschild, PharmD, MS, MBA: Let’s talk about access and affordability. It’s great to have wonderful therapies for heart failure, but if the patients aren’t able to fill them or they aren’t staying adherent to these therapies, we aren’t going to see those positive health benefits. How do we discuss the population health-management approaches for heart failure but also identify an opportunity for us to improve care? I want to start this first question to Dr Uppal. We talked earlier about how we’re going to treat a lot of these patients the same, whether they have preserved or reduced ejection fraction [EF]. But how do we start to identify and treat patients with heart failure who are at risk for poor health outcomes between one another? How do we stratify those risks to identify tho...
